The UK’s Medicines and Healthcare products Regulatory Agency moved on several fronts in the first half of 2026, with the intention of developing a more innovation-friendly and AI-aware regime. The developments include a landmark program deepening regulatory cooperation between the UK and the United States, a regulatory “sandbox” for AI used as a medical device, meaning a supervised space where companies can test products with the regulator before full authorization, an evidence-gathering exercise on how AI in healthcare should be regulated, a consultation on a draft Rare Disease Therapies Regulatory Framework, and the largest package of UK clinical trial reforms in more than twenty years. For a founder building AI-enabled diagnostics, software, or therapeutics, this changes both the route to market and its timing: earlier regulator engagement is becoming possible, trial rules are being streamlined, and closer UK-US alignment may reduce duplicated work across the two markets.
